



RESISTENT INFECTION
A Huge Concern That Should be overcome

CUBIST (CBST)
Just On Time

Resistant infection has become a primary world concern. In hospitals, patients are contracting deadly strains of resistant staphylococcus infection following a long stay or surgery. While the stories about victims of this ugly phenomenon are accumulating, Cubist (CBST) announced after the closing bell on Monday that the Phase 3 trial of its drug, Cubicin, are positive for staphylococcus aureus **endocarditis** and **bacteremia**. **The trial met its primary endpoints.**

Cubist expects to file a supplemental new drug application with the FDA before the end of the year to seek approval to add staphylococcus **aureus endocarditis** and **bacteremia** to the **Cubicin label**.

The press release stated that a Phase 3 clinical trial had shown Cubicin to be successful in treating patients with endocarditis (heart infection) and bacteremia (blood infection.)

Cubicin is already on the market for the treatment of complicated skin infections, which is a much smaller market than that of the new indications.

The excellent news for Cubist is that **the results have exceeded the scientists' expectations**. The firm intends to present the new emerging data to the broader scientific community and share it with the FDA.

Analysts could not hide their enthusiasm. Most have already upgraded the stock. We believe that the news has come at a time when an effective treatment for those resistant organisms has become a life-saving necessity. With the Phase 3 data in hand, we believe Cubist will get a fast approval.

Read Prohost projections about Cubist in the upcoming Faxletter/E-mail letter, which will be posted later in the day.

PROHOST RESEARCH
P.O. BOX 640 429
Oakland Gardens, Ny 11364
Telephone : 516 678 1335
Fax 718 423 2731
E-mail prohost@aol.com

Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: <http://www.sec.gov/consumer/cyberfr.htm>